<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; MerckSerono</title>
	<atom:link href="http://www.tapanray.in/tag/merckserono/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Just Born A Pharma Goliath: Would India Be Impacted?</title>
		<link>http://www.tapanray.in/just-born-a-pharma-goliath-would-india-be-impacted/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=just-born-a-pharma-goliath-would-india-be-impacted</link>
		<comments>http://www.tapanray.in/just-born-a-pharma-goliath-would-india-be-impacted/#comments</comments>
		<pubDate>Mon, 03 Mar 2014 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Actavis]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[chilcott]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[CRAMS]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Forest]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Goliath]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[MerckSerono]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[multinational]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Seksharia]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[super]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US-FDA]]></category>
		<category><![CDATA[Watson]]></category>
		<category><![CDATA[Zentiva]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5030</guid>
		<description><![CDATA[Just born a potential pharma Goliath, as Actavis &#8211; the Dublin-based one of the largest global generic drug makers, in its biggest ever purchase, acquires New York based R&#38;D based pharma major &#8211; Forest Laboratories, for a whopping US$ 25 billion. &#8230; <a href="http://www.tapanray.in/just-born-a-pharma-goliath-would-india-be-impacted/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/just-born-a-pharma-goliath-would-india-be-impacted/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Big Pharma: Now A ‘Chink in Its Armor’?</title>
		<link>http://www.tapanray.in/big-pharma-now-a-chink-in-its-armour/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharma-now-a-chink-in-its-armour</link>
		<comments>http://www.tapanray.in/big-pharma-now-a-chink-in-its-armour/#comments</comments>
		<pubDate>Mon, 17 Feb 2014 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[&]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[Armour]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Chamber]]></category>
		<category><![CDATA[Chink]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[GIPC]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Johnson]]></category>
		<category><![CDATA[lobbying]]></category>
		<category><![CDATA[MerckSerono]]></category>
		<category><![CDATA[NovoNordisk]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[South]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USTR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5000</guid>
		<description><![CDATA[Emerging trends bring to the fore a possible ‘Chink in the Armor’ of the ‘Big Pharma’, despite a number of recent belligerent moves. One such move I had deliberated in my earlier blog post. There I mentioned that 2014 report &#8230; <a href="http://www.tapanray.in/big-pharma-now-a-chink-in-its-armour/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharma-now-a-chink-in-its-armour/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
